Agreement between Kedrion and ProMetic for the development of Hyperimmune products

Kedrion S.p.A. and ProMetic Life Sciences Inc. (TSX:PLI) announced that they have signed the definitive agreement for two hyperimmunes. The first product to be developed will target the Hepatitis B Hyperimmune.

Kedrion has in-licensed ProMetic’s technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in Europe will be paid by Kedrion to ProMetic with ProMetic retaining the commercial rights for the fully developed hyperimmune products for the North American market. ProMetic will in turn pay Kedrion royalties on its sales of the hyperimmune products in North America.

The product development program, including the clinical trial designed to meet U.S. and European regulatory requirements, will be funded by Kedrion. Full scale commercial manufacturing will then take place in Kedrion’s facility in Italy. Kedrion will be the holder of the products registration for both markets.

“This is a deal that leverages each company's expertise to bring a new generation of products for a better compliance of the patients, especially targeting the hyperimmune market that is considered strategic for Kedrion” explained Mr. Paolo Marcucci, President and CEO of Kedrion.

"This agreement with Kedrion will leverage ProMetic’s ability to penetrate into the North American hyperimmune product market and expand on our existing revenue base" commented Mr. Pierre Laurin, President and CEO of ProMetic.

For information about ProMetic Life Sciences Inc.

For more information please contact: [email protected]